Wanli Kang,Jian Du,Song Yang,Hongyan Chen,Jianxiong Liu,Jinshan Ma,Mingwu Li,Jingmin Qin,Wei Shu,JiaJia Yu,Peilan Zong,Yi Zhang,Yongkang Dong,Zhiyi Yang,Zaoxian Mei,Qunyi Deng,Pu Wang,Wenge Han,Meiying Wu,Ling Chen,Xinguo Zhao,Lei Tan,Fujian Li,Chao Zheng,Hongwei Liu,Xinjie Li,Ertai A,Yingrong Du,Fenglin Liu,Wenyu Cui,Quanhong Wang,Xiaohong Chen,Junfeng Han,Qingyao Xie,Yanmei Feng,Wenyu Liu,Peijun Tang,Jianyong Zhang,Jian Zheng,Dawei Chen,Xiangyang Yao,Tong Ren,Yang Li,Yuanyuan Li,Lei Wu,Qiang Song,Mei Yang,Jian Zhang,Yuanyuan Liu,Shuliang Guo,Kun Yan,Xinghua Shen,Dan Lei,Yangli Zhang,Xiaofeng Yan,Liang Li,Shenjie Tang

Abstract:Background: Tuberculosis remains a serious and substantial global public health problem today. Pulmonary tuberculosis (PTB) is the most common clinical presentation of TB. In clinical practice, PTB patients have concurrent many types of co-morbidities such as pneumonia, liver disorder, diabetes mellitus, hematological disorder, malnutrition, hemoptysis, etc. This causes the condition of PTB patients complicated. Detecting and treating specific co-morbidities and preventing their development are important for PTB patients. However, the prevalence of most co-morbid conditions in patients with PTB is not well described.Methods: We conducted a large-scale, multi-center, observational study using admission data at 21 hospitals in China from Jan 1, 2011 to Dec 31, 2017, to elucidate and illustrate the prevalence rates of major co-morbidities in inpatients admitted to hospital for pulmonary TB. The 20 specific co-morbidities were selected for analysis in this patient cohort, and stratified the patient cohort according to age and gender.Findings: A total of 355,929 PTB inpatients were included, with a male:female ratio of 1.97 and the median age 47 (IQR:28~62) years old. The prevalence of 20 specific co-morbidities in patients with PTB was analyzed, with pneumonia being the most common co-morbidity. The prevalence of most co-morbidities were higher in males with PTB except thyroid disorders, mental health disorders, etc. The prevalence of defined most co-morbidities in patients with PTB tended to increase with increasing age, although some specific co-morbidities tended to increase initially then decrease with increasing age.Interpretation: Early identification and management of co-morbidities in patients with PTB may positively influence treatment outcomes for PTB patients. Our study, together with future research into co-morbidity trends in non-hospitalized PTB patients, may be useful in determining community based prevalence rates for PTB co-morbidities, thus enhancing diagnostic and therapeutic decision-making, and clinical outcomes in all PTB patients.Funding Statement: Key Project of Chinese National Programs (Grant No. 2015ZX10003001), ‘Beijing Municipal Administration of Hospitals’ Ascent Plan (No. DFL20181601) and Tongzhou District Science and Technology Committee [No.KJ2017CX054].Declaration of Interests: All the authors declare no conflicts of interest.Ethics Approval Statement: The Ethics Committee of Beijing Chest Hospital, Capital Medical University approved this study with a waiver of informed consent from the patients involved.

The Prevalence and Risks of Major Co-Morbidities among Patients with Pulmonary Tuberculosis in China from a Gender and Age Perspective: A Large-Scale Multi-Center Observational Study